Scarica l'app Stockscreener
26.69
0.96%
-0.26
Dopo l'orario di chiusura:
28.02
1.33
+4.98%
Precedente Chiudi:
$26.95
Aprire:
$26.91
Volume 24 ore:
126.52K
Relative Volume:
2.24
Capitalizzazione di mercato:
$934.11M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-10.94%
1M Prestazione:
+4.79%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$26.28
$27.27
Intervallo di 1 settimana:
$26.28
$30.40
Portata 52W:
$22.51
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
(720) 940-2200
Indirizzo
10170 CHURCH RANCH WAY, WESTMINSTER
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Oruka Therapeutics to Present at Multiple November Investor Conferences - StockTitan
Oruka stock draws buy rating at Stifel (NASDAQ:ORKA) - Seeking Alpha
Oruka Therapeutics shares gain buy rating as H.C. Wainwright sees strong future in psoriasis treatment - Investing.com Canada
Oruka Therapeutics Adjusts Executive Severance Agreements - TipRanks
Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga
Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada
Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian
Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - StockTitan
Ordell Minerals Advances Gold Prospects with Phase 2 Drilling - TipRanks
Orkla ASA (OTCMKTS:ORKLY) Sets New 1-Year High at $9.47 - Defense World
Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia
Orora (OTCMKTS:ORRYY) Shares Up 32.6% - Defense World
Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga
‘Omni Loop’ takes a bit too much on its plate - Daily Trojan Online
Private Auckland hospital doubles in size: New $3m robot, extra beds, surgical expansion - New Zealand Herald
Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha
‘Omni Loop’ (2024) Movie ReviewNothing New | MOVIESR.NET - Midgard Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts - Defense World
Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal
Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners - Defense World
Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Ocugen Inc [OCGN] Stock bought by Insider RAMESH KUMAR for $0.15 million - Knox Daily
‘Omni Loop’ Review: Sci-Fi Indie Offers Some Ham-Fisted Heart - Observer
Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
TD Cowen Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Leerink Partners starts drug developer Oruka with 'outperform' - XM
Oruka Therapeutics initiated with an Outperform at Leerink - TipRanks
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections - Benzinga
Roche scores first, with FDA approval of Ocrevus Zunovo for MS - The Pharma Letter
Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology
Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group - Defense World
Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments - TipRanks
FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - STAT
Oruka to advance psoriasis programs into clinic next year - BioWorld Online
Jefferies starts Oruka Therapeutics with buy, $40 target - Investing.com UK
Biotech firm enters $200M agreement - The Business Journals
Oruka Therapeutics secures $200 million in PIPE financing By Investing.com - Investing.com Canada
Oruka Therapeutics sets clinical trial dates for skin disease drugs - Investing.com
Oruka Therapeutics secures $200 million in PIPE financing - Investing.com
Oruka Therapeutics Announces $200 Million Private Placement - GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines - GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wedbush - Defense World
Arca Biopharma, Oruka Therapeutics merger complete - Boulder Daily Camera
Oruka Therapeutics (NASDAQ:ORKA) Receives New Coverage from Analysts at Wedbush - Defense World
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Non sono disponibili dati finanziari per Oruka Therapeutics Inc (ORKA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Oruka Therapeutics Inc Azioni (ORKA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 08 '24 |
Buy |
3.46 |
47,492 |
164,190 |
1,724,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 05 '24 |
Buy |
3.43 |
28,326 |
97,065 |
1,676,903 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 09 '24 |
Buy |
3.43 |
16,917 |
58,091 |
1,741,312 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):